Ovid Therapeutics Inc. (OVID)

NASDAQ: OVID · USD

$2.45

+0.19 (+8.4%)· Recorded snapshot

Market cap	478.5M
Revenue (ttm)	1.6M
Net income (ttm)	-34.5M
EPS (ttm)	-$0.28
Shares out	195.3M
Volume	1,867,118
Beta	0.23

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 1.6M
Net income (ttm): -34.5M
EPS (ttm): -$0.28
Market cap: 478.5M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Trzymaj

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-26

P25 n/aP50 n/aP75 n/a

ROIC-72

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All OVID indicators

Market & fundamental data

Available fields

199

Groups with data

Currency

USD

Showing 199 of 199 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001636651
Company name	Ovid Therapeutics Inc.
Country	United States
Country code	US
CUSIP number	690469101
Earnings date	2026-11-11
Earnings time	bmo
Employees	23
Employees change	-17
Employees growth	-42.5%
Enterprise value	$321.4M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2014
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2017-05-05
Is primary listing	Yes
Is SPAC	No
ISIN number	US6904691010
Last 10-K release date	2026-03-18
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$478.5M
Market cap category	Small-Cap
Next earnings date	2026-11-11
Options	Yes
Price	$2.45
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	OVID
U.S. state	New York
Website	https://www.ovidrx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-11.58%
EV/Sales	206.13x
FCF / EV yield	-16.79%
FCF yield	-11.33%
Forward EV/Sales	2,409.6x
Forward P/S	3,569.36x
P/B ratio	1.99x
P/S ratio	305.35x
Price / tangible book value	2.3x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Operating margin	-3,667.59%
Pretax margin	-2,178.84%
Profit per employee	$-1.5M
Revenue per employee	$68,826
ROA	-23.46%
ROA (5Y)	-7.84%
ROCE	-26.15%
ROE	-25.96%
ROE (5Y)	-4.74%
ROIC	-72.03%
SBC / revenue	302.02%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	3
Gross profit growth	-76.2%
Gross profit growth (Q)	-88.31%
Gross profit growth 3Y	99.83%
Gross profit growth 5Y	-62.76%
Net income growth years	3
Revenue growth	-76.2%
Revenue growth (Q)	-88.31%
Revenue growth 3Y	99.83%
Revenue growth 5Y	-62.76%
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$84,000
EBIT	$-58.1M
EBITDA	$-58M
EPS	$-0.28
FCF per share	$-0.28
Financing cash flow	$185.8M
Free cash flow	$-54.8M
Free cash flow minus SBC	$-59.6M
Gross profit	$1.6M
Investing cash flow	$-147.8M
Net cash flow	$-17.1M
Net income	$-34.5M
Operating cash flow minus SBC	$-59.6M
Operating income	$-58.1M
Revenue	$1.6M
Stock-based compensation	$4.8M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	3.45
Book value per share	$1.14
Debt / equity	0.06
Long-term assets	$108.4M
Long-term liabilities	$12.1M
Net cash (debt)	$157.1M
Net cash / market cap	32.49%
Net cash growth	547.7%
Net debt / equity	-0.75
Piotroski F-Score	1
Property, plant and equipment	$11.2M
Shareholders' equity	$209.9M
Tangible book value	$209.9M
Tangible book value per share	$1.14
Total assets	$232M
Total cash	$117.2M
Total debt	$12.7M
Total liabilities	$22.1M
WACC	5.37%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.01
Current assets	$123.6M
Current liabilities	$10M
Current ratio	12.39
Net working capital	$-2.1M
Quick ratio	11.75
Working capital	$113.6M
Working capital turnover	0.02

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-71.09%
Dividend yield	0%
Shareholder yield	-71.09%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$2.55
1D price change	8.41%
1M price change	2.29%
1M total return	2.29%
1W price change	4.03%
1W total return	4.03%
1Y price change	53.44%
1Y return CAGR	53.48%
1Y total return	53.44%
20-day SMA	$2.31
200-day SMA	$2.35
3M price change	4.47%
3M total return	4.47%
3Y price change	-24.92%
3Y return CAGR	-9.11%
3Y total return	-24.92%
50-day SMA	$2.55
50-day SMA vs 200-day SMA	50over200
52-week high	$3.11
52-week high date	2026-04-09
52-week low	$1.18
52-week low date	2025-11-14
5Y price change	-28.84%
5Y return CAGR	-6.58%
5Y total return	-28.84%
6M price change	-8.74%
6M total return	-8.74%
All-time high	$15.93
All-time high date	2017-05-18
All-time low	$0.24
All-time low date	2025-04-09
Average true range (ATR)	$0.17
Average volume	1.7M
Beta (1Y)	1.76
Beta (2Y)	2.08
Beta (5Y)	0.23
Change from 52-week high	-21.1%
Change from 52-week low	107.63%
Change from all-time high	-84.59%
Change from all-time low	912.37%
Change from open	6.52%
Day's gap	1.77%
Dollar volume	$4.6M
High price	$2.50
Low price	$2.26
Monthly RSI	57.15
Open price	$2.30
Position in 52-week range	80.85%
Premarket change	-1.33%
Premarket close	$2.26
Premarket price	$2.23
Premarket volume	896
Previous close	$2.26
Price vs 150-day SMA	-3.8%
Price vs 20-day SMA	6.09%
Price vs 200-day SMA	4.29%
Price vs 50-day SMA	-3.73%
Relative volume	1.07
RSI	53.26
Sharpe ratio	0.89
Sharpe ratio (3Y)	0.42
Sharpe ratio (5Y)	0.34
Sortino ratio	1.5
Sortino ratio (3Y)	0.67
Sortino ratio (5Y)	0.56
Volume	1.9M
Weekly RSI	51.49
YTD price change	50.61%
YTD total return	50.61%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	163.4M
Float percentage	83.66%
Shares change (QoQ)	45%
Shares change (YoY)	71.09%
Shares held by insiders	2.18%
Shares held by institutions	71.03%
Shares outstanding	195.3M
Short % of float	11.06%
Short % of shares	9.25%
Short ratio	10.2 days

Deeper analysis on OVID

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this OVID report

Is a complete OVID research report available?

No complete published report is available for Ovid Therapeutics Inc. (OVID) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Ovid Therapeutics Inc. (OVID)

Price

Financial snapshot

Fair-value bridge

Latest news · OVID

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All OVID indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on OVID

Frequently asked questions